Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by ramrodretired on Feb 19, 2023 11:44am

ASCO

Did anyone hear how the PRESENTATION went?
Comment by plantrader on Feb 19, 2023 12:52pm
Here's the link on the ASCO site: https://meetings.asco.org/abstracts-presentations/216828 Would be nice to hear how it went. 
Comment by plantrader on Feb 19, 2023 1:22pm
First 42 patients, 21% CR at 450 days
Comment by Oilminerdeluxe on Feb 19, 2023 1:25pm
I think we are at 28% now.
Comment by gebremeskel on Feb 19, 2023 2:35pm
https://www.urotoday.com/conference-highlights/asco-gu-2023/asco-gu-2023-bladder-cancer/142518-asco-gu-2023-528-a-phase-ii-clinical-study-of-intravesical-photo-dynamic-therapy-in-patients-with-bcg-unresponsive-nmibc-interim-analysis.html
Comment by DJDawg on Feb 19, 2023 6:18pm
I can't say for sure as I was not at this meeting but I have attended other meetings like it. The presentation is sometimes just a poster on display with the author present. Or it can be a poster and then a short presentation to go with it. In this case, the urotoday article makes it clear that they presented the same response rates as the Nov 29 company update. Which has to do with the rules ...more  
Comment by Legit62 on Feb 19, 2023 7:34pm
I totally agree with you DJDawg, but unfortunately my feeling is we will not hear a word until they announce BTD, IMO but still hoping
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250